Calixto João B, Medeiros Rodrigo, Fernandes Elizabeth S, Ferreira Juliano, Cabrini Daniela A, Campos Maria M
Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, 88049-900 Florianópolis, SC, Brazil.
Br J Pharmacol. 2004 Dec;143(7):803-18. doi: 10.1038/sj.bjp.0706012. Epub 2004 Nov 1.
Kinins are a family of peptides implicated in several pathophysiological events. Most of their effects are likely mediated by the activation of two G-protein-coupled receptors: B(1) and B(2). Whereas B(2) receptors are constitutive entities, B(1) receptors behave as key inducible molecules that may be upregulated under some special circumstances. In this context, several recent reports have investigated the importance of B(1) receptor activation in certain disease models. Furthermore, research on B(1) receptors in the last years has been mainly focused in determining the mechanisms and pathways involved in the process of induction. This was essentially favoured by the advances obtained in molecular biology studies, as well as in the design of selective and stable peptide and nonpeptide kinin B(1) receptor antagonists. Likewise, development of kinin B(1) receptor knockout mice greatly helped to extend the evidence about the relevance of B(1) receptors during pathological states. In the present review, we attempted to remark the main advances achieved in the last 5 years about the participation of kinin B(1) receptors in painful and inflammatory disorders. We have also aimed to point out some groups of chronic diseases, such as diabetes, arthritis, cancer or neuropathic pain, in which the strategic development of nonpeptidic oral-available and selective B(1) receptor antagonists could have a potential relevant therapeutic interest.
激肽是一族与多种病理生理事件相关的肽类。它们的大多数作用可能是通过激活两种G蛋白偶联受体介导的:B(1)和B(2)。B(2)受体是组成型实体,而B(1)受体则是关键的可诱导分子,在某些特殊情况下可能会上调。在此背景下,最近有几份报告研究了B(1)受体激活在某些疾病模型中的重要性。此外,过去几年对B(1)受体的研究主要集中在确定诱导过程中涉及的机制和途径。分子生物学研究的进展以及选择性和稳定的肽类和非肽类激肽B(1)受体拮抗剂的设计极大地推动了这一研究。同样,激肽B(1)受体基因敲除小鼠的培育极大地有助于扩展有关B(1)受体在病理状态下相关性的证据。在本综述中,我们试图阐述过去5年中激肽B(1)受体参与疼痛和炎症性疾病方面取得的主要进展。我们还旨在指出一些慢性疾病组,如糖尿病、关节炎、癌症或神经性疼痛,在这些疾病中,开发非肽类口服可用且选择性的B(1)受体拮抗剂可能具有潜在的相关治疗意义。